{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:22Z","timestamp":1791920902868,"version":"4.3.4"},"reference-count":45,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,1,13]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Non-Hodgkin\u2019s lymphoma (NHL) is currently the most common malignancy among people living with HIV (PLWH) in the USA. NHL in PLWH is more frequently associated with oncogenic viruses than NHL in immunocompetent individuals and is generally associated with increased PD-1 expression and T cell exhaustion. An effective immune-based second-line approach that is less immunosuppressive than chemotherapy may decrease infection risk, improve immune control of oncogenic viruses, and ultimately allow for better lymphoma control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study of patients with HIV-associated lymphomas treated with pembrolizumab\u00b1pomalidomide in the HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 10 patients with stage IV relapsed and\/or primary refractory HIV-associated NHL who were treated with pembrolizumab, an immune checkpoint inihibitor, with or without pomalidomide. Five patients had primary effusion lymphoma (PEL): one had germinal center B cell-like (GCB) diffuse large B cell lymphoma (DLBCL); two had non-GCB DLBCL; one had aggressive B cell lymphoma, not otherwise specified; and one had plasmablastic lymphoma. Six patients received pembrolizumab alone at 200\u2009mg intravenously every 3 weeks, three received pembrolizumab 200\u2009mg intravenously every 4 weeks plus pomalidomide 4\u2009mg orally every day for days 1\u201321 of a 28-day cycle; and one sequentially received pembrolizumab alone and then pomalidomide alone. The response rate was 50% with particular benefit in gammaherpesvirus-associated tumors. The progression-free survival was 4.1 months (95% CI: 1.3 to 12.4) and overall survival was 14.7 months (95%\u2009CI: 2.96 to not reached). Three patients with PEL had leptomeningeal disease: one had a complete response and the other two had long-term disease control. There were four immune-related adverse events (irAEs), all CTCAEv5 grade 2\u20133; three of the four patients were able to continue receiving pembrolizumab. No irAEs occurred in patients receiving the combination of pembrolizumab and pomalidomide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment of HIV-associated NHL with pembrolizumab with or without pomalidomide elicited responses in several subtypes of HIV-associated NHL. This approach is worth further study in PLWH and NHL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-002097","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T11:13:44Z","timestamp":1613733224000},"page":"e002097","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin\u2019s lymphoma"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01495598","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02659930","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00006518","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00092222","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01419561","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-7292","authenticated-orcid":false,"given":"Kathryn","family":"Lurain","sequence":"first","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Mangusan","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaida","family":"Widell","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ekwede","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jomy","family":"George","sequence":"additional","affiliation":[{"name":"Clinical Pharmacokinetics Research Lab, Clinical Center Pharmacy, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ambinder","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cheever","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L","family":"Gulley","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila H","family":"Goncalves","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6959-0924","authenticated-orcid":false,"given":"Thomas S","family":"Uldrick","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"Division of Global Oncology, Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-1395","authenticated-orcid":false,"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"2025100302100417000_9.2.e002097.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60604-8"},{"key":"2025100302100417000_9.2.e002097.2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000428"},{"key":"2025100302100417000_9.2.e002097.3","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12823"},{"key":"2025100302100417000_9.2.e002097.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180315"},{"key":"2025100302100417000_9.2.e002097.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0432"},{"key":"2025100302100417000_9.2.e002097.6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17960"},{"key":"2025100302100417000_9.2.e002097.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444."},{"key":"2025100302100417000_9.2.e002097.8","doi-asserted-by":"publisher","DOI":"10.1038\/nm1482"},{"key":"2025100302100417000_9.2.e002097.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"2025100302100417000_9.2.e002097.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766"},{"key":"2025100302100417000_9.2.e002097.11","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100302100417000_9.2.e002097.12","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of Durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100302100417000_9.2.e002097.13","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2016.69.3812","article-title":"Pomalidomide for symptomatic Kaposi's sarcoma in people with and without HIV infection: a phase I\/II study","volume":"34","author":"Polizzotto","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025100302100417000_9.2.e002097.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113595"},{"key":"2025100302100417000_9.2.e002097.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-828418"},{"key":"2025100302100417000_9.2.e002097.16","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.245"},{"key":"2025100302100417000_9.2.e002097.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.744"},{"key":"2025100302100417000_9.2.e002097.18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1546544","article-title":"Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells","volume":"8","author":"Davis","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100302100417000_9.2.e002097.19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing treatment of HIV-associated lymphoma","volume":"134","author":"Noy","year":"2019","journal-title":"Blood"},{"key":"2025100302100417000_9.2.e002097.20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0029"},{"key":"2025100302100417000_9.2.e002097.21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0066"},{"key":"2025100302100417000_9.2.e002097.22","doi-asserted-by":"crossref","first-page":"11552","DOI":"10.1200\/JCO.2020.38.15_suppl.11552","article-title":"A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases","volume":"38","author":"Ramaswami","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"2025100302100417000_9.2.e002097.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"2025100302100417000_9.2.e002097.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100302100417000_9.2.e002097.25","unstructured":"United States Department of Health and Human Services . Common terminology criteria for adverse events version 5.0, 2020. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"2025100302100417000_9.2.e002097.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-893339"},{"key":"2025100302100417000_9.2.e002097.27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2025100302100417000_9.2.e002097.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841"},{"key":"2025100302100417000_9.2.e002097.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-833806"},{"key":"2025100302100417000_9.2.e002097.30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.141978"},{"key":"2025100302100417000_9.2.e002097.31","doi-asserted-by":"crossref","DOI":"10.4103\/1742-6413.168059","article-title":"Human immunodeficiency virus-associated primary effusion lymphoma: an exceedingly rare entity in cerebrospinal fluid","volume":"12","author":"Jain","year":"2015","journal-title":"Cytojournal"},{"key":"2025100302100417000_9.2.e002097.32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/neup.12353","article-title":"Primary effusion lymphoma involving cerebrospinal fluid, deep cervical lymph nodes and adenoids. Report of a case supporting the lymphatic connection between brain and lymph nodes","volume":"37","author":"Santonja","year":"2017","journal-title":"Neuropathology"},{"key":"2025100302100417000_9.2.e002097.33","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00277-020-04140-0","article-title":"Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell\/follicular grade 3B lymphoma","volume":"99","author":"Kuitunen","year":"2020","journal-title":"Ann Hematol"},{"key":"2025100302100417000_9.2.e002097.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8021"},{"key":"2025100302100417000_9.2.e002097.35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0148"},{"key":"2025100302100417000_9.2.e002097.36","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283635232"},{"key":"2025100302100417000_9.2.e002097.37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.clml.2016.11.005","article-title":"Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma","volume":"17","author":"Judd","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025100302100417000_9.2.e002097.38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2019.4648","article-title":"Immune status and associated mortality after cancer treatment among individuals with HIV in the antiretroviral therapy era","volume":"6","author":"Calkins","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100302100417000_9.2.e002097.39","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.2020006048","article-title":"Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate","volume":"136","author":"Lurain","year":"2020","journal-title":"Blood"},{"key":"2025100302100417000_9.2.e002097.40","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199803)57:3&lt;266::AID-AJH25&gt;3.0.CO;2-7"},{"key":"2025100302100417000_9.2.e002097.41","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115"},{"key":"2025100302100417000_9.2.e002097.42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11904-020-00525-y","article-title":"Anti-PD-1 and anti-PD-L1 monoclonal antibodies in people living with HIV and cancer","volume":"17","author":"Lurain","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025100302100417000_9.2.e002097.43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1546544","article-title":"Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells","volume":"8","author":"Davis","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100302100417000_9.2.e002097.44","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of clinical Oncology-Friends of cancer research HIV Working group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100302100417000_9.2.e002097.45","unstructured":"Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B virus or hepatitis C virus infections: food and drug administration guidance for industry. Available: https:\/\/www.fda.gov\/media\/121319\/download [Accessed 1 September 2020]."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-002097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:10:14Z","timestamp":1759482614000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-002097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,19]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/jitc-2020-002097"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-002097","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}